In contrast to other Bcl-2 family members, MCL-1 is usually not involved in translocations; also mutations of MCL-1 are very infrequent (detected in approximately 1% of all cancers) [27] although they were shown to prolong MCL-1 stability and affect the activity of MCL-1 inhibitors [28]. This evidence concerns the gene BCL2 and cancer.